Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases

CAMBRIDGE, Mass., Jan. 27, 2020 /PRNewswire/ -- Quench Bio, a company leveraging new insights into gasdermin biology and innate immunology to develop medicines for severe inflammatory diseases, today announced the completion of a $50 million Series A financing led by RA Capital Management...

from PR Newswire: https://ift.tt/2tUfEWz